Clovis Oncology, Inc.
CLVSDelisted Dec 29, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001466301
Clovis Oncology, Inc. was delisted on Dec 29, 2022; its insiders filed their last Form 4 on Nov 3, 2022; 103 institutions reported holding it in 13F filings for Q3 2022, worth $42.6M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 103
- Q3 2022, −12 vs. previous quarter
- 13F value
- $42.6M
- Reported value at the end of Q3 2022
- Superinvestors holding
- 0
- At the end of Q3 2022
Superinvestors holding CLVS, Q3 2022
No superinvestor reported holding CLVS at the end of Q3 2022.
Latest insider trades
Open-market purchases and sales by Clovis Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 3, 2022 (view filing) | Nov 2 | 1 day | Gross Paul EdwardSee Remarks | SSale | −4.73K | $0.98 | −$4.64K | −4.6%98.3K after | 2 lots |
| Nov 3, 2022 (view filing) | Nov 2 | 1 day | Ivers-Read Gillian CSee Remarks | SSale | −3.68K | $0.98 | −$3.61K | −1.2%293.6K after | 2 lots |
| Nov 3, 2022 (view filing) | Nov 2 | 1 day | Harding Thomas C.See Remarks | SSale | −1.70K | $0.98 | −$1.67K | −8.0%19.5K after | 2 lots |
| Nov 3, 2022 (view filing) | Nov 2 | 1 day | Harding Thomas C.See Remarks | SSale | −63 | $0.98 | −$61.74 | −1.6%3.80K after | |
| Nov 3, 2022 (view filing) | Nov 2 | 1 day | Muehl Daniel WSee Remarks | SSale | −4.58K | $0.98 | −$4.49K | −4.2%104.8K after | 2 lots |
| Nov 3, 2022 (view filing) | Nov 2 | 1 day | Rolfe LindseySee Remarks | SSale | −4.26K | $0.98 | −$4.18K | −3.6%113.7K after | 2 lots |
| Oct 4, 2022 (view filing) | Oct 3 | 1 day | Harding Thomas C.See Remarks | SSale | −6 | $1.29 | −$7.74 | −0.2%3.68K after | |
| Sep 6, 2022 (view filing) | Sep 2 | 4 days | Rolfe LindseySee Remarks | SSale | −2.54K | $1.20 | −$3.05K | −2.3%109.6K after | |
| Sep 6, 2022 (view filing) | Sep 2 | 4 days | Gross Paul EdwardSee Remarks | SSale | −2.31K | $1.20 | −$2.77K | −2.4%92.8K after | |
| Sep 6, 2022 (view filing) | Sep 2 | 4 days | Harding Thomas C.See Remarks | SSale | −1.44K | $1.20 | −$1.73K | −7.5%17.8K after |
Top 10 13F holders, Q3 2022
The largest institutional positions in Clovis Oncology, Inc. at the end of Q3 2022; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 10,206,509 | $12.1M | 0.00% | −1,016,728−9.1% | Reduced |
| Palo Alto Investors LP | 4,473,967 | $5.32M | 0.42% | 00.0% | Unchanged |
| BlackRock Inc. | 4,035,344 | $4.80M | 0.00% | −686,873−14.5% | Reduced |
| QVT Financial LP | 3,525,000 | $4.20M | 0.34% | +1,425,000+67.9% | Added |
| Renaissance Technologies LLC | 2,209,700 | $2.63M | 0.00% | −78,600−3.4% | Reduced |
| Geode Capital Management, LLC | 1,382,968 | $1.65M | 0.00% | +5,258+0.4% | Added |
| Millennium Management LLC | 976,384 | $1.16M | 0.00% | −4,423,940−81.9% | Reduced |
| State Street Corp | 715,398 | $851.0K | 0.00% | +111,500+18.5% | Added |
| Pinnacle Associates Ltd | 620,203 | $738.0K | 0.02% | −82,501−11.7% | Reduced |
| Wellington Management Group LLP | 560,565 | $667.0K | 0.00% | +93,913+20.1% | Added |